ReviewCVIR endovascular2026
Clinical management of portal vein thrombosis in cirrhosis: an evidence‑based narrative review.
Review in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal vein thrombosis (PVT) complicates up to a third of patients with cirrhosis and is associated with variceal bleeding, refractory ascites, and challenges at liver transplantation. Management has evolved from selective anticoagulation to broader use of endovascular therapies, especially transjugular intrahepatic portosystemic shunt (TIPS) and portal vein recanalisation strategies. In this narrative review, we summarise the current evidence for anticoagulation, thrombolysis, TIPS, and surgery, and compare major society guidelines. Meta-analyses in cirrhosis show that anticoagulation increases recanalisation and reduces thrombus progression without increasing major bleeding and may lower variceal bleeding risk. Endovascular meta-analysis demonstrates high feasibility of TIPS for PVT (~ 95%) with a 12-month portal vein recanalisation around 80% and shunt patency ~ 84% with major complications observed in ~ 10%. Additional catheter-directed thrombolysis during TIPS may increase severe complications and is not routinely recommended in patients with cirrhosis. Guidelines broadly recommend anticoagulation for recent, clinically significant PVT and reserve TIPS for patients with portal hypertension complications, failure of anticoagulation, or transplantation candidacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.